These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36830896)

  • 1. Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing.
    Sperotto A; Bochicchio MT; Simonetti G; Buccisano F; Peccatori J; Piemontese S; Calistri E; Ciotti G; Pierdomenico E; De Marchi R; Ciceri F; Gottardi M
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
    Ahn JS; Kim T; Jung SH; Ahn SY; Jung SY; Song GY; Kim M; Yang DH; Lee JJ; Choi S; Lee JY; Park SK; Moon JH; Lee HY; Kim KH; Cai Y; Yi SY; Novitzky-Basso I; Zhang Z; Kim HJ; Kim DDH
    Bone Marrow Transplant; 2021 May; 56(5):1159-1170. PubMed ID: 33279940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
    Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
    Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
    PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Gaut D; Mead M
    Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of Residual Disease in Acute Myeloid Leukemia.
    Vedula RS; Lindsley RC
    Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments.
    Simonsen AT; Meggendorfer M; Hansen MH; Nederby L; Koch S; Hansen M; Rosenberg CA; Kern W; Nyvold CG; Aggerholm A; Haferlach T; Ommen HB
    Exp Hematol; 2022 Mar; 107():51-59. PubMed ID: 35122908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
    Klyuchnikov E; Langebrake C; Badbaran A; Dadkhah A; Massoud R; Freiberger P; Ayuk F; Janson D; Wolschke C; Bacher U; Kröger N
    Eur J Haematol; 2023 Feb; 110(2):188-197. PubMed ID: 36335432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mythological chimera and new era of relapse prediction post-transplant.
    Ciurea SO; Kothari A; Sana S; Al Malki MM
    Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
    Buccisano F; Walter RB
    Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
    Logan AC
    Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.